Several other analysts have also recently issued reports on the company. Zacks Investment Research raised Galectin Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 19th. HC Wainwright reissued a buy rating on shares of Galectin Therapeutics in a research report on Friday, April 1st.
Shares of NASDAQ GALT opened at $1.74 on Friday. The company has a current ratio of 4.63, a quick ratio of 4.63 and a debt-to-equity ratio of 79.37. The stock has a market capitalization of $103.25 million, a PE ratio of -3.35 and a beta of 1.72. The stock’s fifty day simple moving average is $1.82 and its two-hundred day simple moving average is $2.37. Galectin Therapeutics has a 12-month low of $1.50 and a 12-month high of $5.70.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Galectin Therapeutics by 0.7% in the 4th quarter. BlackRock Inc. now owns 793,025 shares of the company’s stock worth $1,642,000 after purchasing an additional 5,443 shares in the last quarter. Virtu Financial LLC acquired a new stake in Galectin Therapeutics during the 4th quarter worth about $37,000. Synovus Financial Corp acquired a new stake in Galectin Therapeutics during the 4th quarter worth about $99,000. Millennium Management LLC lifted its position in Galectin Therapeutics by 15.8% during the 4th quarter. Millennium Management LLC now owns 405,601 shares of the company’s stock worth $840,000 after acquiring an additional 55,265 shares during the period. Finally, Geode Capital Management LLC lifted its position in Galectin Therapeutics by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 559,728 shares of the company’s stock worth $1,158,000 after acquiring an additional 18,862 shares during the period. 12.25% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile (Get Rating)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Lululemon Rises On Wave Of Price Target Increases
- 3 Stellar Steel Stocks to Buy Now
- The Top Is In For Infosys
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- Three Beaten Up Stocks The Insiders Are Buying
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.